How Will U.S. Orthopaedic Partners Deal Shape Johnson & Johnson’s (JNJ) Medtech Growth Strategy?

• In the past week, U.S. Orthopaedic Partners announced a new agreement selecting Johnson & Johnson as its official vendor for total joint products, giving the physician-led platform access to advanced medtech solutions including robotic-assisted technology.
• This collaboration highlights growing demand for clinically-driven product selection and operational efficiency, as well as the increasing influence of physician-led organizations in medtech partnerships.
• We'll explore how Johnson & Johnson's expanded medtech partnership supports its investment outlook and aligns with analysts' expectations for future earnings growth.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Johnson & Johnson Investment Narrative Recap

Owning Johnson & Johnson stock often means believing in the company’s ability to offset product-specific challenges with continued innovation and scale, particularly through its MedTech and Innovative Medicine divisions. The newly expanded partnership with U.S. Orthopaedic Partners strengthens Johnson & Johnson’s MedTech footprint, but given the current focus on pharmaceutical exclusivity, especially STELARA, the agreement does not alter the company’s most important short-term earnings catalyst or address its key risk of biosimilar competition eroding revenue.

The recent FDA approval of TREMFYA® for pediatric psoriasis and psoriatic arthritis stands out for its potential to support the Innovative Medicine segment by extending the drug’s reach. This announcement underscores how Johnson & Johnson is working to broaden its therapeutic franchises amid ongoing headwinds, which remains crucial while its orthopedics business attempts to regain momentum through new partnerships and product launches.

Yet, against these positive developments, investors should remember that loss of exclusivity in critical drug portfolios is still a major concern that could ...

Read the full narrative on Johnson & Johnson (it's free!)

Johnson & Johnson's projections estimate $104.1 billion in revenue and $22.9 billion in earnings by 2028. This outlook is based on a 4.7% annual revenue growth rate and a modest $0.2 billion increase in earnings from current earnings of $22.7 billion.

Uncover how Johnson & Johnson's forecasts yield a $179.64 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Thirty members of the Simply Wall St Community estimate JNJ’s fair value between US$133 and US$442.56 per share. While views range widely, the loss of exclusivity for major drugs remains a central theme influencing expectations, inviting you to explore differing outlooks on Johnson & Johnson’s next phase.

Explore 30 other fair value estimates on Johnson & Johnson - why the stock might be worth 29% less than the current price!

Build Your Own Johnson & Johnson Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 35 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com